ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-DLL3 Antibody-drug Conjugate BL-M14D1

Also written as “BL-M14D1” and “BL-M14D1 and Atezolizumab”.

In Sichuan Biokin Pharmaceutical’s pipeline, DLL3 ADC. Its studies are mostly in Small Cell Lung Carcinoma · Carcinoma, Neuroendocrine, led by 2 companies.

Drug pageAnti-DLL3 Antibody-drug Conjugate BL-M14D1: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 12, 20264 company-led studies, 4 open or runningNext primary completion: Jun 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biokin (Shanghai) Biopharmaceuticalits history only22 open or runningphase 2since Jun 12, 2026Jul 11, 2024Jun 2027phase 1 · NCT06505824
Sichuan Biokin Pharmaceuticalits history only22 open or runningphase 3since May 21, 2026Jul 14, 2025Dec 31, 2027phase 1 · NCT07080242
  • Named in Sichuan Biokin Pharmaceutical’s own pipeline as BL-M14D1 (DLL3 ADC), phase 3, as of Nov 16, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 11, 2024First study: phase 1 study in Small Cell Lung CarcinomaNew to Biokin (Shanghai) BiopharmaceuticalBiokin (Shanghai) Biopharmaceutical · NCT06505824 · 115 planned · China
  2. Jul 14, 2025Sichuan Biokin Pharmaceutical’s first study: phase 1 study in Carcinoma, NeuroendocrineNew to Sichuan Biokin PharmaceuticalSichuan Biokin Pharmaceutical · NCT07080242 · 120 planned · United States, Georgia, Ukraine
  3. May 21, 2026Phase 3 study in Small Cell Lung CarcinomaPhase 3 reachedSichuan Biokin Pharmaceutical · NCT07625644 · 550 planned · United States, Australia, Bulgaria and more
  4. Jun 12, 2026Phase 2 study in Small Cell Lung CarcinomaPhase 2 reachedBiokin (Shanghai) Biopharmaceutical · NCT07654400 · 36 planned · China

Ahead

  1. Jun 2027Primary completion: phase 1 study in Small Cell Lung CarcinomaBiokin (Shanghai) Biopharmaceutical · NCT06505824
  2. Dec 2027Primary completion: phase 2 study in Small Cell Lung CarcinomaBiokin (Shanghai) Biopharmaceutical · NCT07654400
  3. Dec 31, 2027Primary completion: phase 1 study in Carcinoma, NeuroendocrineSichuan Biokin Pharmaceutical · NCT07080242
  4. Jan 2030Primary completion: phase 3 study in Small Cell Lung CarcinomaSichuan Biokin Pharmaceutical · NCT07625644

TargetBeta

“DLL3 ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3) ”NCIt, by rule

Other programs on DLL3

ProgramCompanyFurthest phaseStudies
tarlatamabruleAmgenphase 313
AlveltamigruleSuzhou Zelgen Biopharmaceuticalsphase 311
obrixtamigBoehringer Ingelheimphase 311
Zocilurtatug PelitecanruleZai Labphase 36
gocatamigMerckphase 34
Autologous Anti-DLL3 CAR-T Cells DJI136Novartisphase 22
Anti-DLL3 Antibody-drug Conjugate IDE849ideaya-biosciencesphase 22
SHR-7787Jiangsu HengRui Medicinephase 21
Anti-DLL3 Antibody-drug Conjugate FZ-AD005ruleShanghai Fudan-Zhangjiang Bio-Pharmaceuticalphase 12
clesitamigHoffmann-La Rochephase 12
Actinium Ac 225-ABD147ruleabdera-therapeutics-incphase 11
Indium In 111-ETN029Novartisphase 11

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07654400Small Cell Lung Carcinoma · China2RecruitingBiokin (Shanghai) BiopharmaceuticalDec 202736
NCT07625644Small Cell Lung Carcinoma · United States, Australia, Bulgaria and more3RecruitingSichuan Biokin PharmaceuticalJan 2030550
NCT07080242Carcinoma, Neuroendocrine · United States, Georgia, Ukraine1RecruitingSichuan Biokin PharmaceuticalDec 31, 2027120
NCT06505824Small Cell Lung Carcinoma · China1RecruitingBiokin (Shanghai) BiopharmaceuticalJun 2027115

How it is read

Names in the registry

  • “BL-M14D1”, 3 entries
  • “BL-M14D1 and Atezolizumab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.